Adjuvant Licensing Hawaii Biotech owns a proprietary saponin vaccine adjuvant that could boost immunogenicity in partner vaccines, providing a licensing or development collaboration opportunity with vaccine developers targeting high threat diseases.

Pipeline Partnerships An active vaccine pipeline against West Nile virus, Zika, tick borne flaviviruses, Crimean Congo hemorrhagic fever, and Chikungunya presents versatile collaboration or licensing options for larger vaccine companies and government biodefense programs.

Toxin Countermeasures HBI is advancing small molecule anti toxin drugs against bacterial toxins such as anthrax lethal factor and botulinum toxin, offering potential to team with defense, public health, or pharmaceutical safety programs for countermeasures.

Pandemic Readiness Past work on second generation Covid vaccines suggests readiness to partner on next generation coronavirus platforms or universal vaccines with industry or government partners seeking pandemic preparedness capabilities.

Funding Readiness A track record of government funding and mid market revenue implies readiness for grant backed programs and joint ventures with federal agencies or defense contractors to advance vaccine and biodefense initiatives.